Merck still has a chance at being part of the Covid-19 treatment landscape.
The FDA is convening an advisory committee on Tuesday to consider the company’s antiviral pill, molnupiravir. But the discussion will highlight the drug’s limitations, including safety risks and limited efficacy, which could cut expectations for the drug’s long-term sales even more.
Analysts…